Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Longeveron Inc. - Class A Common stock (NQ: LGVN )

1.670 +0.100 (+6.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
Research and development of stem cell-based therapies, where a patient’s own cells, or those from a donor, are used to fight injury and disease, is one of the fastest... 
Via Benzinga
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent decrease in Tie-2 at Day 270 Oral... 
Via Benzinga
NASDAQ:LGVN Investor Notice: Lawsuit Alleges Securities Laws Violations by Longeveron Inc.
San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investor, who purchased shares of Longeveron Inc. (NASDAQ:LGVN), filed a lawsuit over alleged violations of Federal Securities Laws by Longeveron Inc. in... 
Via SBWire
Topics Initial Public Offering Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
EXCLUSIVE: Longeveron Announces Biomarker Analysis Data From Mid-Stage Study Of Anti-Aging Cell Therapy Candidate
Longeveron Inc. (NASDAQ: LGVN) announced Wednesday positive biomarker analysis data from the mid-stage study of its lead cell therapy candidate in aging frailty subjects. What... 
Via Benzinga
LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron
Photo by jesse orrico on Unsplash Researchers in the medical field are constantly working to create medicines to prevent and cure diseases. The development of the multiple COVID-... 
Via Benzinga
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LGVN
From Rosen Law Firm
Via Business Wire
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
--Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. --Secondary... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff... 
Via Benzinga
EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study
Longeveron Inc. (NASDAQ: LGVN), a cell therapy company developing therapies for age-related and life-threatening conditions, reported Thursday final results from a Phase 1 study... 
Via Benzinga
NASDAQ:LGVN Investor Notice: Investigation over Possible Securities Laws Violations by Longeveron Inc.
San Diego, CA -- (SBWIRE) -- 09/02/2021 -- Longeveron Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
38 Stocks Moving In Monday's Mid-Day Session
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of... 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares rose 26.6% to $12.87 in pre-market trading after the company disclosed that after reviewing its earlier-reported Phase II... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE... 
Via Benzinga
78 Biggest Movers From Friday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biolase (NASDAQ:BIOL) stock increased by 38.01% to $0.87 during Friday's regular session. Trading volume for this security as of 12:35 EST is 80.8 million,... 
Via Benzinga
53 Stocks Moving In Friday's Mid-Day Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... 
Via Benzinga
How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients
Via FinancialNewsMedia
Stocks That Hit 52-Week Lows On Friday
Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the largest company in terms of market cap to set a new 52-week... 
Via Benzinga
EXCLUSIVE: Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not Met
Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced... 
Via Benzinga
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.